The present application relates to a pharmaceutical composition comprising a combination of an FXR agonist and at least one additional therapeutic agent that lowers the glucose level in the blood stimulates insulin secretion and/or increases insulin sensitivity. The present application relates to use of the pharmaceutical composition for the treatment or prevention of a FXR mediated disease or condition such as NAFLD and NASH a disease or condition related to an elevated level of glucose in the blood decreased secretion of insulin and/or decreased insulin sensitivity such as hyperglycemia diabetes obesity and insulin resistance or for lowering the glucose level in the blood stimulating insulin secretion and/or increasing insulin sensitivity.
